These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 6138921)
1. On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. With particular reference to dopaminergic mechanisms in the central nervous system. Hjorth S Acta Physiol Scand Suppl; 1983; 517():1-52. PubMed ID: 6138921 [TBL] [Abstract][Full Text] [Related]
9. Dopamine receptors involved in prolactin secretion pharmacologically characterized by means of 3-PPP enantiomers. Eriksson E; Modigh K; Carlsson A; Wikström H Eur J Pharmacol; 1983 Dec; 96(1-2):29-36. PubMed ID: 6662196 [TBL] [Abstract][Full Text] [Related]
10. Dopamine (DA) autoreceptor efficacy of 3-PPP enantiomers after short-term synaptic DA deprivation. Hjorth S; Clark D; Carlsson A Eur J Pharmacol; 1988 Aug; 152(3):207-15. PubMed ID: 3146512 [TBL] [Abstract][Full Text] [Related]
11. Indolizidine and quinolizidine derivatives of the dopamine autoreceptor agonist 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP). Bøgesø KP; Arnt J; Lundmark M; Sundell S J Med Chem; 1987 Jan; 30(1):142-50. PubMed ID: 3806591 [TBL] [Abstract][Full Text] [Related]
12. Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. Clark D; Hjorth S; Carlsson A J Neural Transm; 1985; 62(3-4):171-207. PubMed ID: 2863323 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites. Koch SW; Koe BK; Bacopoulos NG Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267 [TBL] [Abstract][Full Text] [Related]
14. Postsynaptic dopamine agonistic effects of 3-PPP enantiomers revealed by bilateral 6-hydroxy-dopamine lesions and by chronic reserpine treatment in rats. Arnt J; Hyttel J J Neural Transm; 1984; 60(3-4):205-23. PubMed ID: 6441835 [TBL] [Abstract][Full Text] [Related]
15. Effects of S (+)-3-phenethyl-PP, a putative dopamine autoreceptors agonist with greater autoreceptor selectivity than 3-PPP enantiomers. Arnt J; Bøgesø KP; Hyttel J; Larsen JJ; Svendsen O Eur J Pharmacol; 1984 Jun; 102(1):91-9. PubMed ID: 6148247 [TBL] [Abstract][Full Text] [Related]
16. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist. Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334 [TBL] [Abstract][Full Text] [Related]
17. Enantiomers of 3-(3,4-dihydroxyphenyl)- and 3-(3-hydroxyphenyl)-N-n-propylpiperidine: central pre- and postsynaptic dopaminergic effects and pharmacokinetics. Rollema H; Mastebroek D; Wikström H; Svensson K; Carlsson A; Sundell S J Med Chem; 1986 Oct; 29(10):1889-95. PubMed ID: 3761308 [TBL] [Abstract][Full Text] [Related]
18. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation. Oberlander C; Boissier JR J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905 [TBL] [Abstract][Full Text] [Related]
19. Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. Clark D; Hjorth S; Carlsson A J Neural Transm; 1985; 62(1-2):1-52. PubMed ID: 3894582 [TBL] [Abstract][Full Text] [Related]
20. The effect of the enantiomers of 3-PPP on conditioned avoidance responding in the rat. Clark D; Carlsson A; Hjorth S; Engel J; Lindberg P Psychopharmacology (Berl); 1983; 81(1):14-7. PubMed ID: 6138790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]